Home  |  Contact

UniProtKB/Swiss-Prot Q13224: Variant p.Gly820Glu

Glutamate receptor ionotropic, NMDA 2B
Gene: GRIN2B
Variant information

Variant position:  820
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Disease [Disclaimer]
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants implicated in disease according to literature reports.
  • Polymorphism: Variants not reported to be implicated in disease.
  • Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:  From Glycine (G) to Glutamate (E) at position 820 (G820E, p.Gly820Glu).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from glycine (G) to medium size and acidic (E)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -2
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Involvement in disease:  Mental retardation, autosomal dominant 6, with or without seizures (MRD6) [MIM:613970]: A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRD6 additional features may include seizures, hypotonia, abnormal movements, such as dystonia, and autistic features. {ECO:0000269|PubMed:20890276, ECO:0000269|PubMed:23033978, ECO:0000269|PubMed:23160955, ECO:0000269|PubMed:24863970, ECO:0000269|PubMed:25356899, ECO:0000269|PubMed:27839871, ECO:0000269|PubMed:28095420}. Note=The disease is caused by mutations affecting the gene represented in this entry.
The name and a short description of the disease associated with the variant. For more information about the disease, the user can refer to OMIM, following the link provided after the disease acronym.

Variant description:  In MRD6.
Any additional useful information about the variant.



Sequence information

Variant position:  820
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  1484
The length of the canonical sequence.

Location on the sequence:   ICHNEKNEVMSSQLDIDNMA  G VFYMLGAAMALSLITFICEH
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         ICHNEKNEVMSSQLDIDNMAGVFYMLGAAMALSLITFICEH

                              ICHNEKNEVMSSQLDIDNMAGVFYMLGAAMALSLITFICEH

Mouse                         ICHNEKNEVMSSQLDIDNMAGVFYMLGAAMALSLITFICEH

Rat                           ICHNEKNEVMSSQLDIDNMAGVFYMLGAAMALSLITFICEH

Xenopus laevis                ICHNEKNEVMSSQLDIDNMAGVFYMLAAAMALSLITFIMEH

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 27 – 1484 Glutamate receptor ionotropic, NMDA 2B
Transmembrane 818 – 837 Helical
Mutagenesis 818 – 818 M -> V. Increased glutamate and glycine agonist potency.


Literature citations

De novo mutations in moderate or severe intellectual disability.
Hamdan F.F.; Srour M.; Capo-Chichi J.M.; Daoud H.; Nassif C.; Patry L.; Massicotte C.; Ambalavanan A.; Spiegelman D.; Diallo O.; Henrion E.; Dionne-Laporte A.; Fougerat A.; Pshezhetsky A.V.; Venkateswaran S.; Rouleau G.A.; Michaud J.L.;
PLoS Genet. 10:E1004772-E1004772(2014)
Cited for: VARIANT MRD6 GLU-820;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.